Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.74 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.72 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5499648 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2784153 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL1332594 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL6676390 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL1332983 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL2785481 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL6658904 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL17395722 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2787592 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL527281 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642440-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2025-11-05 | — | — | EP | claimed |
| WO-2024141760-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2024-07-04 | — | — | WO | claimed |
| CN-114076701-A | Dried blood spot quality control product for newborn screening and preparation method thereof | 上海安谱实验科技股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-111196764-A | Method for synthesizing lauroyl L-carnitine hydrochloride | 黄冈华阳药业有限公司 | 2020-05-26 | — | — | CN | claimed |
| CN-109498559-A | A kind of oral preparation and preparation method thereof loading treating diabetes polypeptide | 复旦大学 | 2019-03-22 | — | — | CN | claimed |
| US-20160082026-A1 | Ganglioside Transmucosal Formulations | LZ THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | claimed |
| US-20150283158-A1 | Ganglioside Transmucosal Formulations | LZ THERAPEUTICS INC (US) | 2015-10-08 | — | — | US | claimed |
| CN-101774934-B | Method for synthesizing lauroyl L-carnitine hydrochloride | HUBEI HILE CHEMICAL TECHNOLOGY CO LTD | 2012-12-12 | — | — | CN | claimed |
| US-20120220544-A1 | Ganglioside Transmucosal Formulations | LZ THERAPEUTICS, INC. | 2012-08-30 | — | — | US | claimed |
| EP-2473174-A2 | GANGLIOSIDE TRANSMUCOSAL FORMULATIONS | LZ Therapeutics, Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| WO-2011028799-A2 | GANGLIOSIDE TRANSMUCOSAL FORMULATIONS | LAZARUS THERAPEUTICS, INC. (US) | 2011-03-10 | — | — | WO | claimed |
| CN-101774934-A | Method for synthesizing lauroyl L-carnitine hydrochloride | HUBEI HILE CHEMICAL TECHNOLOGY | 2010-07-14 | — | — | CN | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | disclosed |
| EP-4680265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | Viking Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-0929270-A1 | ORAL PEPTIDE PHARMACEUTICAL PRODUCTS | Unigene Laboratories, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5912014-A | COMPOUNDS FOR TREATMENT OF BONE DISORDERS | UNIGENE LABORATORIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| CN-1213282-A | Oral peptide pharmaceutical products | UNIGENE LAB INC (US) | 1999-04-07 | — | — | CN | disclosed |
| WO-1997033531-A1 | ORAL PEPTIDE PHARMACEUTICAL PRODUCTS | UNIGENE LABORATORIES, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | HSP90AA1 216/4885GLA 3979/4885HRH1 2561/4885 |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | HSP90AA1 2907/4885GLA 983/4885HRH1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.